Livewell’s response to COVID-19 treatment and prevention advert

An advert circulating on social media platforms in Zimbabwe generated by Livewell (PVT) Ltd. about a COVID-19 treat and prevent package called ZIVERDOKIT (Zinc Acetate, Ivermectin, and Doxycycline), caused a public outcry regarding this kit as there is no known cure approved by the World Health Organization (WHO) for COVID-19.

It caught the attention of WHO Zimbabwe and the Medicines Control Authority of Zimbabwe (MCAZ) with the two organisations publicly discrediting the information on the advert.

Further inquiry done by this publication revealed that the said advert was leaked and the perpetrators are not yet known by Livewell. Livewell management issued a letter today the 6th of July addressing this issue.

Below are some of the excerpts from the letter:

“Our management team would like to issue an unreserved apology to the Zimbabwean public, the Ministry of health and Medicines Council of Zimbabwe and the World Health Organization.”

“The advert was created for internal use and was never meant for public consumption. This document was purely to get internal feedback for potential marketing efforts once product stock would be received.”

Ivermectin is a broad-spectrum anti-parasitic agent, included in the WHO essential medicines list for several parasitic diseases.  Doxycycline is an antibiotic used to treat bacterial infections, and zinc acetate is used to treat zinc deficiency. It is also used to boost the immune system, treat the common cold, and prevent lower respiratory tract infections. These may not be the exhaustive uses of these medications as there might be more uses.

Livewell is yet to receive a license to use these medicines and has not been registered yet by MCAZ. It is working with the relevant authorities regarding the leak of the advert.

WHO recommends that Ivermectin only be used within clinical trials to get more data regarding the efficacy of this drug. Some sources believe that doxycycline may be effective in blocking inflammatory storms and, therefore, be a promising treatment of severe COVID-19 patients.

The use of these medicines is still under investigation by medical practitioners, believing that they work and others still skeptical and needing further analysis.